恩瑞格的使用说明

It is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Enrig was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved the new indication of Enriga for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) aged 10 years and above.

Deferasirox needs to be used in sufficient quantity and for a sufficient period of time as prescribed by your doctor. Before the disease is completely controlled, your symptoms may be relieved, but do not reduce the dosage or stop taking the medicine easily.

The recommended starting daily dose of Deferasirox is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered.

Drug interactions: 1. Avoid combination with strong inducers of UDP-glucuronyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors), cholestyramine. 2. It cannot be administered at the same time as aluminum-containing antacids. Not to be combined with other iron chelation treatments. 3. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Pause at least 5 days before performing Gallium-67 imaging.